On April 23, 2026, the FDA approved Otarmeni, a first-of-its-kind gene therapy for genetic hearing loss.

Some facts:

• It targets OTOF gene-associated hearing loss, where patients lack otoferlin (a protein critical for sound signal transmission) due to variants in the gene.This accounts for 2–8% of inherited non-syndromic hearing loss.
• It’s a one-time surgical procedure that delivers a functional copy of the OTOF gene directly into the cochlea, restoring otoferlin production at the biological level.
• In the clinical trial, 80% of evaluable patients experienced improved hearing, which is an outcome not expected in the natural history of (deafness as a disease) without intervention.
• It’s approved for both pediatric and adult patients, including children as young as 10 months.

via:

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | FDA

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.

www.fda.gov ↗

Of course, this is a medical triumph. But for language, it’s also more complicated than that.

The Deaf community and cochlear implants

First, a primer, courtesy of Wikipedia ¹.

A cochlear implant is a surgically implanted neuroprosthesis that provides a person who has moderate-to-profound sensorineural hearing loss with sound perception. With the help of therapy, cochlear implants may allow for improved speech understanding in both quiet and noisy environments.

A subset of Deaf culture (particularly those who use sign language as their primary language) has long opposed cochlear implants. And to understand why, we must look at it as emerging from a history of hearing people making decisions about deaf people’s language.

It’s 1880, and an international conference of deaf educators are convening in Milan. Despite the subject matter, the vast majority of delegates are hearing. A biased, pre-arranged² series of presentations are given, and resolutions are passed declaring oral education (ie speech and lip-reading) superior to sign language. Schools for the deaf are banned from signing. The American and British delegations were the only objectors, and were outvoted³.

For nearly the whole century afterward, generations of deaf children were educated without access to sign language, often punished for signing, and left to navigate a hearing world through methods that worked inconsistently at best.

As cochlear implants became more mainstream, so did resistance to it from the Deaf community. As I understand it, their main arguments are⁴:

• Deafness is an identity, not a disability. Many in the Deaf community view themselves as a linguistic and cultural minority, not as people with a medical condition that needs “fixing”. Organizations like the National Association of the Deaf have historically pushed back hard on the framing of deafness as something to be “cured.” This is also related to cultural erasure, where there’s a fear that adoption of implants could shrink the Deaf community and erode sign language culture over time.
• Consent. Most implants are done on infants and toddlers, who can’t consent. This imposes a hearing identity on a child before they can decide for themselves.
• Ineffectiveness, sometimes. Cochlear implants don’t restore normal hearing and work better for some than others. If a child is implanted and the implant underperforms, they may end up without fluency in either spoken language or ASL. This leads to a condition researchers have begun calling language deprivation syndrome, which can cause developmental delays, cognitive differences, among other neurological effects.

Correcting the biology

Whereas cochlear implants bypass the underlying biology with a device, the correcting the biology framing of this gene therapy will pose as even more threatening than implants. Perhaps it’s closer to the language of eugenics—fixing a person at the genetic level—which historically has been deeply alarming to disability rights advocates. A cochlear implant is removable, while a gene delivered to the cochlear hair cells is not.

The counterargument is also strong. A delayed diagnosis can lead to missed treatment windows and meaningful speech and language developmental delays, and parents who want their deaf children to have access to spoken language now have a potentially effective, one-time biological option rather than a device.

We now know that first-language fluency must be established within the first ~five years of life for normal neurological development to proceed ⁵.

Otarmeni is approved for children as young as ten months, easily inside that window.

What cochlear implants did to ASL

First, a note on ASL. A common misconception is that American Sign Language (ASL) is a visual shorthand for English, built from hand shapes that “look like” the things they represent. Really, ASL is a fully autonomous natural language with its own phonology (the discrete handshapes, movements, and locations that combine to form signs), its own morphology (signs that inflect for tense, aspect, and agreement), and its own syntax that differs substantially from English. Like all natural languages, it is also productive: its finite set of elements can be combined to express an unlimited range of ideas, including ones that have never been expressed before. The fact that it is transmitted visually rather than acoustically does not make it any less a language, in the same way that writing is not a lesser form of speech.

—

In this way, cochlear implants was seen as threatening ASL’s existence as a language. As for what actually happened? less than feared, but not nothing.

For decades, the dominant clinical advice was to implant the child early, focus entirely on spoken language, and don’t sign. The fear among audiologists and speech therapists was that signing would become a crutch, and that children who had access to a visual language would never fully develop spoken language. This was, in retrospect, the Milan logic repackaged with clinical language, and it had a similar demographic effect.

Indeed, a few decades ago, roughly 80% of deaf and hard-of-hearing children attended residential schools for the deaf. These residential schools were places where Deaf identity and ASL were transmitted intergenerationally as much as they were standard educational institutions.

Today, more than 80% attend their local mainstream schools.

This genocide rhetoric started to turn around in the 1990s.

First, cochlear implants don’t always work. This was known, and children for whom an implant underperforms are left in a worse position than if they’d been immersed in ASL from birth. By the time it becomes clear a child isn’t acquiring spoken language through a cochlear device, the critical window for first-language acquisition may already have closed. What only started registering in literature later was that language deprivation in deaf children can cause permanent differences in brain structure in language-related pathways — not dissimilar to those seen in hearing children raised in conditions of severe neglect⁶, and exactly what advocates of ASL had been warning about.

Then the clinical advice started to catch up. In 2023, the American Academy of Pediatrics (not exactly a bastion of Deaf culture advocacy) published guidelines recommending ASL exposure for deaf children regardless of implant status.⁷

The evidence showed that signing children with cochlear implants develop spoken language at rates comparable to hearing peers, and better than non-signing implanted children. The either-or framing, it turned out, was wrong. Signing was able to scaffold speech acquisition.

So what will Otarmeni do to ASL?

Probably more, and for a subtler reason.

Cochlear implants are devices. They are prosthetic, imperfect, and have failure modes that keep the door to Deaf identity open. A child with a cochlear implant is still, in some meaningful sense, deaf. The implant processes sound artificially which leaves this wide gap between “functional hearing” and natural hearing.⁸

Otarmeni closes this gap. In the clinical trial, some patients achieved normal or near-normal audibility, which, as far as the biology is concerned, is a restoration. A child treated at ten months, before they’ve had a chance to enter Deaf culture at all, may grow up hearing in a way that is neurologically indistinguishable from any other hearing person. This is what makes the gene therapy philosophically harder than the implant debate.

Caveats. Otarmeni only targets OTOF-associated hearing loss, which accounts for 2–8% of inherited non-syndromic cases. The broader landscape of inherited deafness involves hundreds of genes, and most won’t have approved therapies anytime soon, so the immediate demographic impact on ASL will be modest.

But precedent moves faster than medicine. The approval of Otarmeni establishes that genetic hearing loss is, in principle, treatable at the source. As the pipeline expands — and it will — the number of children who are eligible for biological hearing restoration will grow.

I don’t think the Deaf community is wrong to read this approval as the beginning of something larger than itself. Cochlear implants applied pressure to Deaf identity and ASL. What gene therapy may do is change the baseline assumption, from deaf children who can be helped to hear to deaf children who can simply be made hearing. That is a different kind of debate, and one that the conversation on identity, consent, and cultural minorities will have to catch up to.